Heron Therapeutics, Inc
Heron Therapeutics is a U.S.-based commercial-stage biotechnology company focused on acute care and oncology supportive care products. It develops and markets prescription therapies such as ZYNRELEF for postsurgical pain and injectable antiemetics used to prevent chemotherapy- and surgery-related nausea and vomiting.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaProducts used around surgery to reduce postoperative pain and opioid use, centered on ZYNRELEF.
Injectable therapies used to prevent chemotherapy-induced nausea and vomiting, including CINVANTI and SUSTOL.
APONVIE and related antiemetic offerings used in surgical settings to prevent nausea and vomiting.
Tuotteet
Raportoitu · osuus liikevaihdosta- CINVANTI62,5 %
- ZYNRELEF24,6 %
- Aponvie7,5 %
- SUSTOL5,5 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Heron sells primarily into the U.S. healthcare channel through specialty distributors and full-line wholesalers that resell to hospitals and healthcare providers. Its commercial team also targets surgeons, oncologists, nurses, pharmacists, managed care organizations, group purchasing organizations, hospital systems, oncology networks, payors, and government accounts because reimbursement and formulary access are critical to adoption.
Buy Heron's products in the U.S. and resell them to hospitals and providers; they are the direct commercial customers.
Use ZYNRELEF and APONVIE in perioperative care to improve pain control and reduce nausea.
Use CINVANTI and SUSTOL to prevent chemotherapy-induced nausea and vomiting.
Influence coverage, reimbursement, and formulary access, which affect product uptake and net sales.
Negotiate purchasing terms and access for institutional adoption across care networks.
Strategia
Heron's strategy is to expand commercial adoption of its marketed products, especially ZYNRELEF, while maintaining a focused sales model in acute care and oncology. It is also using partnerships such as the Crosslink co-promotion agreement to broaden reach in orthopedic indications and improve product penetration without building a much larger internal field force.
ZYNRELEF is a key growth driver and label expansion broadens the addressable market.
The company depends on a small portfolio of marketed products, so execution directly affects revenue.
Coverage and reimbursement determine whether hospitals and payors adopt the products at scale.
Maantiede
Heron's business is overwhelmingly U.S.-centric, with commercial sales, sales and marketing, and customer relationships concentrated in the United States. The company notes that reimbursement and pricing are country-specific in foreign markets, but the disclosed commercial footprint and product sales described in the reports are primarily domestic.
Riskit
Heron is highly dependent on a small number of commercial products, so any loss of market acceptance, reimbursement pressure, or competitive displacement could materially affect results. The company also faces supply-chain, manufacturing, regulatory, and commercialization risks that are common in specialty pharmaceuticals but especially important because it relies on third-party distribution and a limited product portfolio.
- Dependence on a limited product portfolioVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company's sales are concentrated in a few marketed products, so any weakness in one product can quickly affect total revenue.
Kohdistuu - Reimbursement and pricing pressureVaikutus: KorkeaTodennäköisyys: Kohtalainen
Hospitals, payors, and government programs must accept pricing and coverage for products to gain broad use.
Kohdistuu: U.S. hospital and payor channels
- Supply chain and single-vendor dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company disclosed that certain components may be sourced from a single vendor, creating disruption risk.
Kohdistuu: Manufacturing inputs and third-party suppliers
- Competition and generic entryVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Competing products can reduce market share, pressure pricing, and limit adoption of Heron's therapies.
Kohdistuu: Acute care pain and antiemetic markets
- Regulatory and postmarketing obligationsVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Label expansion, safety monitoring, and FDA requirements can affect commercialization timing and cost.
Kohdistuu: ZYNRELEF and other approved products
Kirjanpito
Harkinnanvaraiset erätNet product sales are reduced by allowances and are recognized at transfer of control, so estimates affect reported revenue.
Vaikutus: Net sales for ZYNRELEF, APONVIE, CINVANTI, and SUSTOL
Commercial products require estimates for obsolescence, excess inventory, and production-related accruals.
Vaikutus: Cost of product sales and gross margin
The company must estimate obligations tied to postmarketing, manufacturing, and development activities.
Vaikutus: Operating expenses and liabilities
As a commercial-stage biotech, equity awards are a meaningful non-cash expense and can affect earnings trends.
Vaikutus: Operating expense and dilution
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Relay Therapeutics, Inc.
RLAY · Biological Products, (No Diagnostic Substances)
Werewolf Therapeutics, Inc.
HOWL · Pharmaceutical Preparations
Sionna Therapeutics, Inc.
SION · Pharmaceutical Preparations
Geron Corporation
GERN · Pharmaceutical Preparations
Geron Corp is a U.S.-based biopharmaceutical company focused on developing and commercializing imetelstat, marketed as RYTELO, for patients with lower-risk myelodysplastic syndromes.
Zynex Inc
ZYXIQ · Electromedical & Electrotherapeutic Apparatus
Kenvue Inc.
KVUE · Perfumes, Cosmetics & Other Toilet Preparations
Päivitetty: 24.9.2026